DE69533940D1 - Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren - Google Patents

Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren

Info

Publication number
DE69533940D1
DE69533940D1 DE69533940T DE69533940T DE69533940D1 DE 69533940 D1 DE69533940 D1 DE 69533940D1 DE 69533940 T DE69533940 T DE 69533940T DE 69533940 T DE69533940 T DE 69533940T DE 69533940 D1 DE69533940 D1 DE 69533940D1
Authority
DE
Germany
Prior art keywords
venous
filators
disulators
antibody
therapeutic compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69533940T
Other languages
English (en)
Other versions
DE69533940T2 (de
Inventor
Wayne H Kaesemeyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogenix Inc
Original Assignee
Angiogenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogenix Inc filed Critical Angiogenix Inc
Application granted granted Critical
Publication of DE69533940D1 publication Critical patent/DE69533940D1/de
Publication of DE69533940T2 publication Critical patent/DE69533940T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DE69533940T 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren Expired - Lifetime DE69533940T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US321051 1981-11-13
US08/321,051 US5543430A (en) 1994-10-05 1994-10-05 Method and formulation of stimulating nitric oxide synthesis
PCT/US1995/012780 WO1996010910A1 (en) 1994-10-05 1995-10-05 Method and formulation of stimulating nitric oxide synthesis

Publications (2)

Publication Number Publication Date
DE69533940D1 true DE69533940D1 (de) 2005-02-24
DE69533940T2 DE69533940T2 (de) 2005-12-22

Family

ID=23248976

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69533940T Expired - Lifetime DE69533940T2 (de) 1994-10-05 1995-10-05 Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69535734T Expired - Lifetime DE69535734D1 (de) 1994-10-05 1995-10-05 Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69535734T Expired - Lifetime DE69535734D1 (de) 1994-10-05 1995-10-05 Therapeutische Zusammensetzungen von Venösdilatoren und Arterielldilatoren

Country Status (12)

Country Link
US (2) US5543430A (de)
EP (2) EP0784429B1 (de)
JP (1) JPH10507443A (de)
AT (2) ATE388700T1 (de)
AU (1) AU705002B2 (de)
CA (1) CA2201784C (de)
DE (2) DE69533940T2 (de)
DK (1) DK0784429T3 (de)
ES (1) ES2236716T3 (de)
MX (1) MX9702527A (de)
PT (1) PT784429E (de)
WO (1) WO1996010910A1 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5945452A (en) * 1993-06-11 1999-08-31 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5968983A (en) * 1994-10-05 1999-10-19 Nitrosystems, Inc Method and formulation for treating vascular disease
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6911427B1 (en) * 1995-09-15 2005-06-28 Duke University No-modified hemoglobins and uses therefore
US6627738B2 (en) 1995-09-15 2003-09-30 Duke University No-modified hemoglobins and uses therefor
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US7968140B2 (en) * 1997-09-08 2011-06-28 Mars, Incorporated Chocolates and chocolate liquor having an enhanced polyphenol content
US5958926A (en) 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) * 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
USRE37234E1 (en) * 1996-11-01 2001-06-19 Nitromed, Inc. Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6436996B1 (en) 1997-09-30 2002-08-20 Duke University Modulation of nitric oxide production
US6147109A (en) * 1997-10-14 2000-11-14 The General Hospital Corporation Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
CA2306096A1 (en) 1997-10-15 1999-04-22 Thomas Jefferson University Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
US6472425B1 (en) * 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
US20020031513A1 (en) * 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US8507018B2 (en) 1998-03-12 2013-08-13 Mars, Incorporated Products containing polyphenol(s) and L-arginine and methods of use thereof
US6805883B2 (en) 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
US6180597B1 (en) 1998-03-19 2001-01-30 Brigham And Women's Hospital, Inc. Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000045809A1 (en) * 1999-02-05 2000-08-10 Nitrosystems, Inc. L-arginine based formulations for treating diseases and methods of using same
EP1175210A4 (de) * 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc Verbesserung der bioverfügbarkeit von arzneimitteln im hirn
US6162237A (en) * 1999-04-19 2000-12-19 Chan; Winston Kam Yew Temporary intravascular stent for use in retrohepatic IVC or hepatic vein injury
US6346382B1 (en) * 1999-06-01 2002-02-12 Vanderbilt University Human carbamyl phosphate synthetase I polymorphism and diagnostic methods related thereto
US9486429B2 (en) * 1999-06-01 2016-11-08 Vanderbilt University Therapeutic methods employing nitric oxide precursors
CA2376375C (en) * 1999-06-05 2011-07-12 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for inhibiting cardiovascular cell proliferation
US7018979B1 (en) 2000-01-26 2006-03-28 Cedars-Sinai Medical Center Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
US6476037B1 (en) * 2000-03-23 2002-11-05 The Regents Of The University Of California L-arginine and phosphodiesterase (PDE) inhibitor synergism
US6784178B2 (en) 2000-04-12 2004-08-31 Cornell Research Foundation, Inc. Pharmacotherapy for vascular dysfunction associated with deficient nitric oxide bioactivity
US6284790B1 (en) 2000-06-15 2001-09-04 Sachin Gupte Methods of potentiating organic nitrates having vasodilating activity and formulations for the same
CA2414941C (en) 2000-08-11 2010-12-14 David R. Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) * 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US20030228564A1 (en) * 2001-05-30 2003-12-11 Edrich Richard Alan Nitric oxide in a pathogen inactivation process
AU2003222569A1 (en) * 2002-01-11 2003-07-24 Whitlock, David R. Compositions including ammonia oxidizing bacteria and methods of using same
US7079888B2 (en) * 2002-04-11 2006-07-18 Ansar, Inc. Method and apparatus for monitoring the autonomic nervous system using non-stationary spectral analysis of heart rate and respiratory activity
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
AU2003284962B2 (en) * 2002-10-24 2009-04-02 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
WO2004071437A2 (en) * 2003-02-07 2004-08-26 Barmensen, Inc. Compositions for enhancing sexual responsiveness
WO2004091626A1 (en) * 2003-04-07 2004-10-28 Osteoscreen, Inc. Bone growth stimulation with no/statin and other no modulating combinations
WO2005030147A2 (en) * 2003-09-26 2005-04-07 Whitlock David R Methods of using ammonia oxidizing bacteria
EP1675619A4 (de) * 2003-09-29 2010-10-06 Palmetto Pharmaceuticals Llc L-arginin-formulierungen mit verzögerter freisetzung und herstellungs- und verwendungsverfahren dafür
US20050095196A1 (en) * 2003-10-29 2005-05-05 Black Keith L. Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor
JP5376761B2 (ja) * 2004-02-23 2013-12-25 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー 身体の外観および皮膚の外観を改善するための、一酸化窒素の局所送達
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102282A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060083724A1 (en) * 2004-10-01 2006-04-20 Hilst Todd W Compositions for the treatment of femal sexual dysfunction
JP2008520694A (ja) * 2004-11-17 2008-06-19 リンジー・バークソン 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
EP1850852A4 (de) * 2005-02-22 2009-11-18 Cedars Sinai Medical Center Verwendung von sildenafil, vardenafil und anderen 5-phosphodiesterase-hemmern zur erhöhung der durchlässigkeit der abnormalen blut-hirn-schranke
US8569369B2 (en) 2007-09-18 2013-10-29 Thermolife International, Llc Amino acid compounds
US8455531B2 (en) 2007-09-18 2013-06-04 Thermolife International, Llc Amino acid compositions
US8466187B2 (en) 2007-09-18 2013-06-18 Thermolife International, Llc Amino acid compositions
US10646508B1 (en) 2007-09-18 2020-05-12 Thermolife International, Llc Method of safely administering nitrate dietary supplements and compositions
US10435356B1 (en) 2007-09-18 2019-10-08 Thermolife International, Llc Amino acid compositions
US10426750B1 (en) 2007-09-18 2019-10-01 Thermolife International, Llc Amino acid supplement formulations
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
KR101932831B1 (ko) * 2008-01-31 2018-12-27 반더빌트유니버시티 관상과 동맥의 동맥류성 지주막하출혈의 치료를 위한 조성물 및 방법
CN101969974A (zh) * 2008-01-31 2011-02-09 范德比尔特大学 对于肺部病症的治疗
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
RU2505291C2 (ru) 2009-06-24 2014-01-27 СТРАТЕДЖИК САЙЕНС ЭНД ТЕКНОЛОДЖИЗ, ЭлЭлСи Топическая композиция, содержащая ибупрофен
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
ES2811515T3 (es) 2010-12-29 2021-03-12 Strategic Science & Tech Llc Tratamiento de disfunción eréctil y otras indicaciones
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
US8936635B2 (en) 2011-03-23 2015-01-20 Palmetto Pharmaceuticals Llc Bioresorbable nitric oxide agonist prodrug scaffolds for vascular stents
AU2012242565B2 (en) 2011-04-13 2017-05-11 Thermolife International, Llc N-Acetyl Beta Alanine methods of use
KR20230165365A (ko) 2014-04-15 2023-12-05 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
KR102396603B1 (ko) 2015-09-16 2022-05-11 원광대학교산학협력단 시트룰린을 유효성분으로 함유하는 간 기능 개선용 조성물
US11865139B2 (en) 2020-11-12 2024-01-09 Thermolife International, Llc Method of treating migraines and headaches

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6191137A (ja) * 1984-10-11 1986-05-09 Kao Corp 外用薬剤組成物
US5059712A (en) * 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) * 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
US5196195A (en) * 1990-03-27 1993-03-23 Cornell Research Foundation, Inc. Use of arginase to control nitric oxide formation
US5273875A (en) * 1991-03-22 1993-12-28 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132453A (en) * 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
US5132407A (en) * 1991-09-26 1992-07-21 Cornell Research Foundation, Inc. Purified inducible nitric oxide synthase flavoprotein
US5286739A (en) * 1991-09-27 1994-02-15 Board Of Regents, University Of Texas System Parenteral formulations for the inhibition of systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
US5266594A (en) * 1992-05-12 1993-11-30 Dawson Valina L Inhibitors of nitric oxide synthase and use thereof to prevent glutamate neurotoxicity
US5281627A (en) * 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof

Also Published As

Publication number Publication date
JPH10507443A (ja) 1998-07-21
ATE287212T1 (de) 2005-02-15
EP0784429B1 (de) 2005-01-19
DK0784429T3 (da) 2005-05-23
PT784429E (pt) 2005-05-31
EP0784429A1 (de) 1997-07-23
DE69533940T2 (de) 2005-12-22
CA2201784A1 (en) 1996-04-18
EP1552745A1 (de) 2005-07-13
CA2201784C (en) 2004-08-24
AU3889695A (en) 1996-05-02
MX9702527A (es) 1998-02-28
EP0784429A4 (de) 2001-02-07
US5543430A (en) 1996-08-06
DE69535734D1 (de) 2008-04-24
US5767160A (en) 1998-06-16
ES2236716T3 (es) 2005-07-16
WO1996010910A1 (en) 1996-04-18
EP1552745B1 (de) 2008-03-12
ATE388700T1 (de) 2008-03-15
AU705002B2 (en) 1999-05-13

Similar Documents

Publication Publication Date Title
DE69533940D1 (de) Therapeutische zusammensetzungen von venösdilatoren und arterielldilatoren
DE69418601T2 (de) Guanidinderivate mit therapeutischer wirkung
DE68902649D1 (de) Lokal anzuwendende arzneizubereitung zur behandlung von entzuendungserkrankungen.
NO20075065L (no) Anvendelse av isoflavonforbindelser til a behandle hjertesykdom
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
CA2286671A1 (en) Method and formulation for treating vascular disease
ATE73331T1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ID24901A (id) Metode pengobatan keadaan terkoagulasi tinggi atau defisiensi protein c yang diperoleh
DE69230046T2 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE4168T1 (de) 2-phenyl-1,2-benzisoselenazol-3(2h)-one enthaltende pharmazeutische zubereitungen und ihre anwendung.
ATE187642T1 (de) Verwendund von norastemizol zur behandlung der allergischen rhinitis
KR880007070A (ko) 백내장 치료용 약학 조성물
DE3773059D1 (de) Ester von salsalat mit guajakol zur behandlung von phlogistischen bronchopneumopathien.
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom
NO20000007D0 (no) Anvendelse av veksthormon i sammensetninger til behandling av insulinresistens i hjertet samt for å oeke proteinkinase-B(PKB)- aktivitet
RU2003118131A (ru) Способ лечения ран
KR880000094A (ko) 위염치료제
DE3575716D1 (de) Pharmazeutische zusammensetzungen mit immunodepressivwirkung.
KR890001555A (ko) 요산 배설용 조성물
RU94036750A (ru) 1,2-дигидро-2-оксо-3-метилсульфониламинометил-пиридины, способ их получения, содержащие их фармацевтические композиции и способ их получения
RU95103161A (ru) Способ лечения хронической гепатитов
RU95102346A (ru) Способ лечения дисциркуляторной энцефалопатии
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition